Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors
Clinical trial NCT02380677 · TERMINATED
Trial details
- NCT number
- NCT02380677
- Sponsor
- NewLink Genetics Corporation
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-04-01
- Primary completion
- 2017-10-04
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.